Florida Attorney General sues Pfizer and CEO over COVID-19 vaccine claims (updated)
UPDATE 1-Florida Attorney General sues Pfizer and CEO over COVID-19 vaccine claims Adds responses from Pfizer and Attorney General's Office in bullets 6 to 8
Oct 1 (Reuters) - Florida Attorney General James Uthmeier on Thursday filed a lawsuit against Pfizer PFE.N and its CEO, Albert Bourla, accusing the drugmaker of misleading consumers about the safety and effectiveness of its COVID-19 vaccine.
Here are more details:
Uthmeier filed the lawsuit in state court, alleging that Pfizer told consumers its COVID-19 vaccine was safe while failing to disclose potential risks, including heart inflammation and other adverse events.
Pfizer, according to the lawsuit, urged people to get the shot to protect others, even though the company never tested whether the vaccine stopped the virus from spreading.
Florida has also accused Pfizer of using unfair tactics to dominate the market.
It said the company made more than $80 billion from vaccine sales, then nearly quadrupled the price of the vaccine to $110 to $130 a dose in 2023 from $30.
The state, suing under its consumer protection law, wants a court order to stop the alleged conduct, fines of $10,000 per violation, or $15,000 when seniors or disabled people were harmed, and the return of profits.
Pfizer said in a statement the state's allegations have no merit and that it would respond to the suit in due course.
"The representations made by Pfizer about its COVID-19 vaccine have been accurate and science-based, and the company stands behind the safety and efficacy of its vaccine," the company said.
"The complaint and comments by Florida Attorney General James Uthmeier speak for themselves," the Florida Attorney General's Office said in response to a Reuters request for additional comment.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shreya Biswas)
((Kamal.Choudhury@thomsonreuters.com;))
Recent news on Pfizer
See all newsFactbox: Pharma sector doubles down on AI to slash costs, timelines
Focus: Beauty giants target 'Ozempic face' as boom in obesity drugs opens new market
Eli Lilly hits record high as healthcare stocks rally
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Factbox: Major drugmakers turn to China for licensing deals